Yifan Pharmaceutical Co., Ltd. (002019.SZ)
CNY 11.34
(-2.99%)
CNY 11.34
(-2.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -882.71 Million CNY | -97.63% |
| 2022 | 399.37 Million CNY | 14.58% |
| 2021 | 348.56 Million CNY | -67.86% |
| 2020 | 1.08 Billion CNY | 0.79% |
| 2019 | 1.07 Billion CNY | 20.75% |
| 2018 | 891.12 Million CNY | -40.85% |
| 2017 | 1.5 Billion CNY | 67.48% |
| 2016 | 899.45 Million CNY | 138.46% |
| 2015 | 377.19 Million CNY | 26.03% |
| 2014 | 299.29 Million CNY | 1080.9% |
| 2013 | 25.34 Million CNY | 889.88% |
| 2012 | -3.2 Million CNY | 98.61% |
| 2011 | -230.12 Million CNY | -23.13% |
| 2010 | -186.88 Million CNY | -721.82% |
| 2009 | 30.05 Million CNY | -45.94% |
| 2008 | 55.59 Million CNY | -84.13% |
| 2007 | 350.25 Million CNY | 4653.99% |
| 2006 | 7.36 Million CNY | -71.83% |
| 2005 | 26.15 Million CNY | -34.49% |
| 2004 | 39.92 Million CNY | 35.33% |
| 2003 | 29.49 Million CNY | 18.1% |
| 2002 | 24.97 Million CNY | -2.7% |
| 2001 | 25.67 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 65.09 Million CNY | -13.25% |
| 2024 Q1 | 133.29 Million CNY | 113.14% |
| 2024 Q2 | 106.24 Million CNY | -20.3% |
| 2023 FY | 9.45 Million CNY | -97.63% |
| 2023 Q2 | 58.25 Million CNY | 31.41% |
| 2023 Q1 | 44.32 Million CNY | 203.23% |
| 2023 Q3 | 22.53 Million CNY | -61.31% |
| 2023 Q4 | -1.01 Billion CNY | -4601.16% |
| 2022 Q1 | 124.23 Million CNY | 291.32% |
| 2022 FY | 399.37 Million CNY | 14.58% |
| 2022 Q2 | 27.93 Million CNY | -77.52% |
| 2022 Q4 | -42.94 Million CNY | -277.32% |
| 2022 Q3 | 24.21 Million CNY | -13.31% |
| 2021 Q4 | -64.93 Million CNY | -203.67% |
| 2021 Q2 | 80.19 Million CNY | -40.29% |
| 2021 Q3 | 62.64 Million CNY | -21.89% |
| 2021 Q1 | 134.3 Million CNY | 1274.89% |
| 2021 FY | 348.56 Million CNY | -67.86% |
| 2020 FY | 1.08 Billion CNY | 0.79% |
| 2020 Q4 | 9.76 Million CNY | -95.75% |
| 2020 Q3 | 230.02 Million CNY | -50.53% |
| 2020 Q2 | 465.02 Million CNY | 22.46% |
| 2020 Q1 | 379.73 Million CNY | 98.49% |
| 2019 Q1 | 183.5 Million CNY | 332.15% |
| 2019 Q2 | 406.65 Million CNY | 121.6% |
| 2019 Q3 | 294.56 Million CNY | -27.56% |
| 2019 Q4 | 191.31 Million CNY | -35.05% |
| 2019 FY | 1.07 Billion CNY | 20.75% |
| 2018 Q4 | 42.46 Million CNY | -78.68% |
| 2018 Q3 | 199.19 Million CNY | -23.19% |
| 2018 FY | 891.12 Million CNY | -40.85% |
| 2018 Q1 | 390.1 Million CNY | -11.76% |
| 2018 Q2 | 259.35 Million CNY | -33.52% |
| 2017 Q4 | 442.1 Million CNY | -10.9% |
| 2017 Q3 | 496.21 Million CNY | 54.23% |
| 2017 Q2 | 321.74 Million CNY | 30.59% |
| 2017 Q1 | 246.38 Million CNY | 30.08% |
| 2017 FY | 1.5 Billion CNY | 67.48% |
| 2016 Q3 | 240.97 Million CNY | -19.14% |
| 2016 Q2 | 298.02 Million CNY | 74.23% |
| 2016 Q1 | 171.05 Million CNY | 103.28% |
| 2016 Q4 | 189.41 Million CNY | -21.4% |
| 2016 FY | 899.45 Million CNY | 138.46% |
| 2015 FY | 377.19 Million CNY | 26.03% |
| 2015 Q3 | 80.15 Million CNY | -22.82% |
| 2015 Q4 | 84.14 Million CNY | 4.98% |
| 2015 Q2 | 103.85 Million CNY | -4.76% |
| 2015 Q1 | 109.04 Million CNY | -27.06% |
| 2014 Q1 | 37.45 Million CNY | 271.93% |
| 2014 Q3 | 39.25 Million CNY | -39.01% |
| 2014 Q4 | 149.49 Million CNY | 280.84% |
| 2014 FY | 299.29 Million CNY | 1080.9% |
| 2014 Q2 | 64.35 Million CNY | 71.82% |
| 2013 FY | 25.34 Million CNY | 889.88% |
| 2013 Q2 | 5.69 Million CNY | 48.06% |
| 2013 Q3 | 5.74 Million CNY | 0.89% |
| 2013 Q4 | 10.07 Million CNY | 75.43% |
| 2013 Q1 | 3.84 Million CNY | 141.81% |
| 2012 Q2 | 7.59 Million CNY | 104.94% |
| 2012 Q1 | 3.7 Million CNY | 101.78% |
| 2012 Q4 | -9.19 Million CNY | -72.72% |
| 2012 FY | -3.2 Million CNY | 98.61% |
| 2012 Q3 | -5.32 Million CNY | -170.04% |
| 2011 Q4 | -208.25 Million CNY | -7648.44% |
| 2011 FY | -230.12 Million CNY | -23.13% |
| 2011 Q1 | -11.73 Million CNY | 93.43% |
| 2011 Q2 | -7.44 Million CNY | 36.59% |
| 2011 Q3 | -2.68 Million CNY | 63.89% |
| 2010 Q2 | -3.79 Million CNY | -233.05% |
| 2010 Q4 | -178.54 Million CNY | -2312.07% |
| 2010 FY | -186.88 Million CNY | -721.82% |
| 2010 Q1 | 2.85 Million CNY | 302.73% |
| 2010 Q3 | -7.4 Million CNY | -95.14% |
| 2009 Q2 | 11.82 Million CNY | 188.38% |
| 2009 Q1 | 4.09 Million CNY | 111.59% |
| 2009 FY | 30.05 Million CNY | -45.94% |
| 2009 Q4 | -1.4 Million CNY | -109.05% |
| 2009 Q3 | 15.53 Million CNY | 31.41% |
| 2008 Q4 | -35.37 Million CNY | -10025.85% |
| 2008 Q2 | 32.8 Million CNY | -43.25% |
| 2008 Q3 | 356.41 Thousand CNY | -98.91% |
| 2008 Q1 | 57.81 Million CNY | -45.32% |
| 2008 FY | 55.59 Million CNY | -84.13% |
| 2007 Q2 | 107.45 Million CNY | 282.27% |
| 2007 FY | 350.25 Million CNY | 4653.99% |
| 2007 Q4 | 105.72 Million CNY | -2.97% |
| 2007 Q3 | 108.96 Million CNY | 1.41% |
| 2007 Q1 | 28.1 Million CNY | 542.94% |
| 2006 Q3 | 5.14 Million CNY | 111.57% |
| 2006 Q1 | 6.14 Million CNY | 366.27% |
| 2006 FY | 7.36 Million CNY | -71.83% |
| 2006 Q2 | 2.42 Million CNY | -60.45% |
| 2006 Q4 | -6.34 Million CNY | -223.44% |
| 2005 Q4 | 1.31 Million CNY | -12.32% |
| 2005 FY | 26.15 Million CNY | -34.49% |
| 2005 Q2 | 12.63 Million CNY | 18.08% |
| 2005 Q1 | 10.69 Million CNY | 64.19% |
| 2005 Q3 | 1.5 Million CNY | -88.11% |
| 2004 Q4 | 6.51 Million CNY | 43.49% |
| 2004 FY | 39.92 Million CNY | 35.33% |
| 2004 Q1 | 14.28 Million CNY | 104.26% |
| 2004 Q2 | 14.57 Million CNY | 2.04% |
| 2004 Q3 | 4.54 Million CNY | -68.85% |
| 2003 Q3 | 3.94 Million CNY | 0.0% |
| 2003 Q4 | 6.99 Million CNY | 77.13% |
| 2003 FY | 29.49 Million CNY | 18.1% |
| 2002 FY | 24.97 Million CNY | -2.7% |
| 2001 FY | 25.67 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 825.98 Million CNY | 206.868% |
| Zhejiang Zhenyuan Share Co., Ltd. | 113.04 Million CNY | 880.878% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -104.37 Million CNY | -745.676% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -141.05 Million CNY | -525.801% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 40.51 Million CNY | 2278.703% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 3.65 Billion CNY | 124.156% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | -56.7 Million CNY | -1456.632% |
| Boai NKY Medical Holdings Ltd. | 585.23 Million CNY | 250.83% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 344.97 Million CNY | 355.878% |